Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients

Blood (2025) 146 (Supplement 1): 2652.

https://doi.org/10.1182/blood-2025-2652

Published: 2025

Journal Articles

Donor age matters: Selecting 10/10 muds under 35 enhances survival after ptcy allo-HCT

Blood (2025) 146 (Supplement 1): 7825.

https://doi.org/10.1182/blood-2025-7825

Published: 2025

Journal Articles

Younger donors, better outcomes: The impact of donor age in haploidentical transplantation for acute myeloid leukemia. study conducted on behalf of geth-TC

Blood (2025) 146 (Supplement 1): 6070.

https://doi.org/10.1182/blood-2025-6070

Published: 2025

Journal Articles

HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30 + lymphoma

Ana Carolina Caballero, Cristina Ujaldón-Miró, Paula Pujol-Fernández, Rosanna Montserrat-Torres, Maria Guardiola-Perello, Eva Escudero-López, Irene Garcia-Cadenas, Albert Esquirol, Rodrigo Martino, Paola Jara-Bustamante, Pol Ezquerra, José Manuel Soria, Eva Iranzo, Maria-Estela Moreno-Martinez, Mireia Riba, Jorge Sierra, Carmen Alvarez-Fernández, Laura Escribà-Garcia, Javier Briones

Blood (2025) 145 (16): 1788–1801.

https://doi.org/10.1182/blood.2024026758

Published: 2025

Includes: Supplemental data

Journal Articles

HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 598.

https://doi.org/10.1182/blood-2024-205686

Published: 2024

Journal Articles

Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 5148.

https://doi.org/10.1182/blood-2024-210442

Published: 2024

Journal Articles

Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 2108.

https://doi.org/10.1182/blood-2024-205181

Published: 2024

Journal Articles

HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30 + T Cell Lymphoma: Clinical Results of a Phase I/II Trial

Ana Carolina Caballero Gonzalez, Laura Escribà-Garcia, Cristina Ujaldón-Miró, Paula Pujol Fernández, Rosanna Montserrat-Torres, Eva Escudero-López, Irene García-Cadenas, Albert Esquirol, Maria Guardiola-Perello, Paola Jara-Bustamante, Rodrigo Martino, Jorge Sierra, Carmen Alvarez-Fernández, Javier Briones

Blood (2024) 144 (Supplement 1): 920.

https://doi.org/10.1182/blood-2024-210129

Published: 2024

Journal Articles

The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC

Blood (2024) 144 (Supplement 1): 405.

https://doi.org/10.1182/blood-2024-210022

Published: 2024

Journal Articles

Efficacy and Safety of Reduced-Doses of Post-Transplant Cyclophosphamide in Matched Peripheral Blood Stem Cell Transplantation, a Multicenter Study

Yadith Karina Lopez-Garcia, Sara Redondo Velao, Andres Gomez-De Leon, Irene García-Cadenas, Héctor Alejandro Vaquera Alfaro, Perla R. Colunga-Pedraza, Albert Esquirol, César Homero Gutierrez-Aguirre, José Carlos Jaime-Pérez, Jorge Sierra, Olga Cantu, Javier Briones, David Gomez-Almaguer, Rodrigo Martino

Blood (2024) 144 (Supplement 1): 4898.

https://doi.org/10.1182/blood-2024-210332

Published: 2024

Journal Articles

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Blood (2024) 144 (Supplement 1): 4884.

https://doi.org/10.1182/blood-2024-204722

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Blood (2023) 142 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2023-174115

Published: 2023

Journal Articles

Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Blood (2023) 142 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2023-185679

Published: 2023

Journal Articles

The Frailty Syndrome As Predictor of Allogeneic Hematopoietic Cell Transplantation Outcomes. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Blood (2023) 142 (Supplement 1): 2346.

https://doi.org/10.1182/blood-2023-190352

Published: 2023

Journal Articles

Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30 + T-Cell Lymphoma: Clinical and Biological Studies

Ana Carolina Carolina Caballero Gonzalez, Laura Escribà-García, Rosanna Montserrat, Eva Escudero-López, Paula Pujol-Fernández, Cristina Ujaldón-Miró, Irene García-Cadenas, Albert Esquirol, Rodrigo Martino, Jorge Sierra, Carmen Alvarez-Fernández, Javier Briones

Blood (2022) 140 (Supplement 1): 405–407.

https://doi.org/10.1182/blood-2022-167504

Published: 2022

Journal Articles

Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

Albert Esquirol, Yolanda Guillén, Elena Bussaglia, Vanesa Criado, Maite Carricondo, Pamela Acha, Manel Esteller, Jorge Sierra, Francesc Solé, Anna Bigas, Josep F Nomdedeu

Blood (2022) 140 (Supplement 1): 11786–11787.

https://doi.org/10.1182/blood-2022-166117

Published: 2022

Journal Articles

Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Blood (2022) 140 (Supplement 1): 7631–7633.

https://doi.org/10.1182/blood-2022-167747

Published: 2022

Journal Articles

Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience from the Spanish Group of Hematopoietic Transplant (GETH-TC)

Blood (2021) 138 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2021-150992

Published: 2021

Journal Articles

Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation

Blood (2019) 134 (Supplement_1): 5733.

https://doi.org/10.1182/blood-2019-126036

Published: 2019

Journal Articles

Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Blood (2017) 130 (Supplement 1): 2025.

https://doi.org/10.1182/blood.V130.Suppl_1.2025.2025

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients

Donor age matters: Selecting 10/10 muds under 35 enhances survival after ptcy allo-HCT

Younger donors, better outcomes: The impact of donor age in haploidentical transplantation for acute myeloid leukemia. study conducted on behalf of geth-TC

HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30 + lymphoma

HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30 + T Cell Lymphoma: Clinical Results of a Phase I/II Trial

The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC

Efficacy and Safety of Reduced-Doses of Post-Transplant Cyclophosphamide in Matched Peripheral Blood Stem Cell Transplantation, a Multicenter Study

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

The Frailty Syndrome As Predictor of Allogeneic Hematopoietic Cell Transplantation Outcomes. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30 + T-Cell Lymphoma: Clinical and Biological Studies

Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience from the Spanish Group of Hematopoietic Transplant (GETH-TC)

Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation

Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only